What is Oncolytics Biotech?
Oncolytics Biotech Inc. operates as a development-stage biopharmaceutical enterprise dedicated to the discovery and advancement of novel pharmaceutical products targeting oncology. At the core of its portfolio is REOLYSIN, an immuno-oncology viral-agent designed to leverage the body's natural immune mechanisms to combat malignant tumors. The company's research framework is structured around three distinct pillars: chemotherapy combinations aimed at selective tumor lysis, immune modulator combinations designed to stimulate innate immune responses, and immuno-therapy combinations intended to foster adaptive immune responses. Founded in 1998 and headquartered in Alberta, Canada, the organization maintains a focused commitment to transforming the standard of care for cancer patients through its proprietary viral-agent platform.
How much funding has Oncolytics Biotech raised?
Oncolytics Biotech has raised a total of $15M across 1 funding round:
Share Placement
$15M
Share Placement (2023): $15M with participation from Leede Jones Gable
Key Investors in Oncolytics Biotech
Leede Jones Gable
Founded in 1965, Leede Jones Gable is an independent, employee-owned firm providing comprehensive financial advice, portfolio management, and insurance services across Canada.
Undisclosed Institutional Investor
Undisclosed investor participating in the funding round.
Undisclosed Institutional Investor
Undisclosed investor participating in the funding round.
What's next for Oncolytics Biotech?
With the recent capital infusion, Oncolytics Biotech is expected to prioritize the clinical progression of its REOLYSIN-based programs. The strategic roadmap likely involves expanding the scope of its chemotherapy and immune modulator combination trials to generate robust data sets required for future regulatory submissions. As the company transitions from early-stage development toward more advanced clinical validation, the focus will remain on optimizing its immuno-therapy combinations to maximize therapeutic efficacy. Investors will be closely monitoring the company's ability to translate its scientific research into tangible clinical outcomes, which will be essential for securing future financing rounds or potential strategic partnerships within the global biopharmaceutical sector.
See full Oncolytics Biotech company page
